1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow COPD (Part 2): new trials by email Literature Review of COPD (Part 2) trials Research Report on COPD (Part 2)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1) - Asthma (Part 1), COPD (Part 2) | Phase 1 | Completed | AstraZeneca | 134 | 2015-10-01 | 2018-11-08 |
Asthma (1) · Pulmonary Disease, Chronic Obstructive (1)
Bronchial Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Hypersensitivity (1) · Respiratory Tract Diseases (1)
AZD-8871 (1) · Tiotropium Bromide (1) · indacaterol (1)
AstraZeneca (1)
United Kingdom (1)
Dave Singh, Prof. (1) · Muna Albayaty, MBChB, MSc,MFPM (1)
2015 (1)